Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News ProPhase Labs Inc. PRPH

ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.


Recent & Breaking News (NDAQ:PRPH)

ProPhase Labs to Present at the Planet MicroCap Showcase: VIRTUAL 2022 on Wednesday, December 7, 2022

GlobeNewswire 13 hours ago

ProPhase Labs Announces Record Third Quarter 2022 Financial Results

GlobeNewswire November 10, 2022

ProPhase Labs Announces Collaboration with Dana-Farber Cancer Institute

GlobeNewswire November 8, 2022

ProPhase Labs to Present at Investor Summit Group's Q4 Conference

GlobeNewswire November 7, 2022

ProPhase Labs to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022 at 11:00 a.m. Eastern Time

GlobeNewswire November 4, 2022

ProPhase Labs Announces Collaboration with G42 Healthcare

GlobeNewswire October 19, 2022

ProPhase Labs to Present at The ThinkEquity Conference

GlobeNewswire October 18, 2022

Nebula Genomics Strengthens Advisory Board with Appointment of Russ Altman, M.D., Ph.D.

GlobeNewswire October 17, 2022

ProPhase Labs to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)

GlobeNewswire September 6, 2022

ProPhase Labs Announces Record Second Quarter 2022 Financial Results

GlobeNewswire August 11, 2022

ProPhase Labs to Host Second Quarter 2022 Financial Results Conference Call on Thursday, August 11, 2022 at 11:00 a.m. Eastern Time

GlobeNewswire August 4, 2022

ProPhase Labs Announces New $6 Million Stock Repurchase Plan

GlobeNewswire July 26, 2022

ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 21, 2022

DSS Announces Licensing of Impact BioMedical's Linebacker Portfolio to ProPhase Labs

GlobeNewswire July 21, 2022

ProPhase Labs Announces Licensing of New Investigational Cancer Compounds

GlobeNewswire July 21, 2022

ProPhase Labs to Host Live Webcast to Discuss Business Developments on Thursday, July 21, 2022

GlobeNewswire July 19, 2022

ProPhase Labs Announces Formation of ProPhase BioPharma, Inc. (PBIO) for the Licensing and Development of Novel Drugs, Compounds and Biotechnology

GlobeNewswire June 28, 2022

Impact BioMedical Announces License Agreement with ProPhase Labs to Produce and Distribute Viral-Fighting Compound Equivir

GlobeNewswire June 28, 2022

ProPhase Labs Announces Significant Laboratory Expansion

GlobeNewswire June 13, 2022

ProPhase Labs to Present at the H.C. Wainwright 2022 Global Investment Conference

GlobeNewswire May 18, 2022